Zunsemetinib free base · Synonyms: ATI-450 | (P)-ATI-450 | CDD450
Zunsemetinib is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 pathway inhibitor.
For research use only. Not for human or veterinary use.
Target
MAPKAPK2 (MK2)
Research area
Inflammation/Immunology
Purity >98%
Stock Inquire
Zunsemetinib structure
CAS No.: 1640282-42-3
Pack sizes & pricing
| Size | Price | SKU | Stock | |
|---|---|---|---|---|
| 25 mg | USD 400.00 | BP-02229-25mg | In stock | Get quote |
| 50 mg | USD 550.00 | BP-02229-50mg | In stock | Get quote |
| 100 mg | USD 850.00 | BP-02229-100mg | In stock | Get quote |
| 250 mg | USD 1,200.00 | BP-02229-250mg | In stock | Get quote |
| 500 mg | USD 1,800.00 | BP-02229-500mg | In stock | Get quote |
| 1 g | USD 2,600.00 | BP-02229-1g | In stock | Get quote |
Description
Zunsemetinib (ATI-450;CDD450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor.
Biological activity
Zunsemetinib (ATI-450;CDD450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases.
Identifiers
- SMILES
-
FC1=CC(F)=CN=C1COC2=C(Cl)C(N(C3=CC(C4=NC(C(C)(C)O)=NC=C4)=NC=C3C)C(C)=C2)=O - InChIKey
-
FQPQMJULRZINPV-UHFFFAOYSA-N
Specifications
- MW (average)
- 513.9240
- Formula
- C25H22ClF2N5O3
- CAS No.
- 1640282-42-3
- Physical state
- Solid
- Color
- White to yellow
- Shipping
- Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
- Storage
- Powder -20℃ 2 years; In solvent -20℃ 1 month;
Solubility
Soluble in DMSO 100 mg/mL
- In vitro
- DMSO : 100 mg/mL
Documents
References
[1]. Zunsemetinib (ATI-450) – Investigational oral MK2 pathway inhibitor
[2]. Aclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in Journal of Experimental Medicine
[3]. Wang C, et al. Selective inhibition of the p38α MAPK-MK2 axis inhibits inflammatory cues including inflammasome priming signals. J Exp Med. 2018;215(5):1315-1325.